Ashutosh S Parihar
Overview
Explore the profile of Ashutosh S Parihar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singh S, Gomez H, Thakkar S, Singh S, Parihar A
Int J Mol Sci
. 2023 Mar;
24(5).
PMID: 36902166
Anti-neoplastic agents for cancer treatment utilize many different mechanisms of action and, when combined, can result in potent inhibition of cancer growth. Combination therapies can result in long-term, durable remission...
2.
Singh S, Murillo G, Richner J, Singh S, Berleth E, Kumar V, et al.
Int J Mol Sci
. 2022 Jul;
23(14).
PMID: 35886918
STAT3 and KRAS regulate cell proliferation, survival, apoptosis, cell migration, and angiogenesis. Aberrant expression of STAT3 and mutant active forms of KRAS have been well-established in the induction and maintenance...
3.
Singh S, Murillo G, Chen D, Parihar A, Mehta R
Breast Cancer (Auckl)
. 2018 Feb;
12:1178223417750858.
PMID: 29434474
Background: The serendipitous discovery of heavy-chain antibodies devoid of light chains in camelids and the subsequent development of VHHs (variable region of camelid heavy chain) have provided a very important...
4.
Shieh C, Trumbull J, Sarthy J, McKenna D, Parihar A, Zhang X, et al.
Assay Drug Dev Technol
. 2004 Apr;
1(5):655-63.
PMID: 15090238
Ligand-gated ion channels (LGICs) play important roles in the regulation of cellular function and signaling and serve as excellent drug targets. However, fast desensitization of most LGICs limits the choice...
5.
Parihar A, Groebe D, Scott V, Feng J, Zhang X, Warrior U, et al.
Assay Drug Dev Technol
. 2004 Apr;
1(5):647-54.
PMID: 15090237
Although techniques such as (86)Rb(+) flux provide a sensitive measure of K(+) channel activity, the relatively short half-life and high-energy emission, together with the quantities of radioactive material generated, hinder...
6.
Parihar A, Coghlan M, Gopalakrishnan M, Shieh C
Eur J Pharmacol
. 2003 Jun;
471(3):157-64.
PMID: 12826234
The effects of 1-ethyl-2-benzimidazolinone (1-EBIO) and riluzole on human prostate cancer cells, LNCaP and PC-3, were evaluated using rubidium (86Rb(+)) efflux and proliferation assays. 1-EBIO and riluzole evoked concentration-dependent increases...
7.
Trumbull J, Maslana E, McKenna D, Nemcek T, Niforatos W, Pan J, et al.
Recept Channels
. 2003 Jun;
9(1):19-28.
PMID: 12825295
The drug discovery process centers around finding and optimizing novel compounds active at therapeutic targets. This process involves direct and indirect measures of how compounds affect the behavior of the...
8.
Turner S, Carroll W, White T, Gopalakrishnan M, Coghlan M, Shieh C, et al.
Bioorg Med Chem Lett
. 2003 Jun;
13(12):2003-7.
PMID: 12781183
2-Amino-4-azaindoles have been identified as a structurally novel class of BK(Ca) channel openers. Their synthesis from 2-chloro-3-nitropyridine is described together with their in vitro properties assessed by 86Rb(+) efflux and...